Anti-inflammatory effects of C-peptide on kidney of type 1 diabetes mellitus animal model

2019 ◽  
Vol 47 (1) ◽  
pp. 721-726 ◽  
Author(s):  
Michelle T. Alves ◽  
Amanda C. S. Chaves ◽  
Ana Paula M. Almeida ◽  
Ana Cristina Simões e Silva ◽  
Stanley de A. Araújo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Animal Model ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide ◽  
Anti Inflammatory

scholarly journals Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: A pilot study

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207065 ◽  
Author(s):  
Catherine A. Sullivan ◽  
Jose M. Cacicedo ◽  
Iniya Rajendran ◽  
Devin W. Steenkamp
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Pilot Study ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide ◽  
Peptide Secretion

scholarly journals Preserved C-peptide levels in overweight or obese compared with underweight children upon diagnosis of type 1 diabetes mellitus

2015 ◽  
Vol 20 (2) ◽  
pp. 92 ◽  
Author(s):  
Hyeoh Won Yu ◽  
Yun Jeong Lee ◽  
Won Im Cho ◽  
Young Ah Lee ◽  
Choong Ho Shin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide

scholarly journals Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3

2016 ◽  
Vol 2016 ◽  
Author(s):  
Marcelo Maia Pinheiro ◽  
Felipe Moura Maia Pinheiro ◽  
Margareth Afonso Torres
Keyword(s):  
Diabetes Mellitus ◽  
Immune Response ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Vitamin D3 ◽  
Clinical Remission ◽  
Insulin Production ◽  
C Peptide ◽  
New Onset

Summary Type 1 diabetes mellitus (T1DM) is a chronic disease characterized by autoimmune destruction of pancreatic beta cells and inadequate insulin production. Remission criteria in T1DM take into account serum levels of C-peptide and glycosylated hemoglobin, as well as the dose of insulin administered to the patient. However, remission of T1DM lasting longer than 1 year is rare. We describe here the cases of two young women who presented with positive glutamic acid decarboxylase (GAD) antibody and classic clinical manifestations of T1DM. Both patients had a prior history of Hashimoto’s thyroiditis. They were initially treated with a basal-bolus regimen of insulin (glargine and lispro/glulisine). Once their blood glucose levels were controlled, they were started on oral sitagliptin 100 mg and vitamin D3 5000 IU daily. After this therapy, both patients achieved clinical diabetes remission for 4 years, along with a decrease in anti-GAD antibody levels. These benefits were probably associated with immunological effects of these medications. Inhibition of dipeptidyl peptidase 4 (DPP-4) in animal models deregulates Th1 immune response, increases secretion of Th2 cytokines, activates CD4+CD25+FoxP3+ regulatory T-cells and prevents IL-17 production. Vitamin D3 also activates CD4+CD25+FoxP3+ regulatory T-cells, and these medications combined can improve the immune response in patients with new-onset T1DM and probably promote sustained clinical remission. Learning points: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production. The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells. Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission. The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission.

scholarly journals Evaluation of Children with Type 1 Diabetes Mellitus in terms of Overweight / Obesity in Tertiary Care Hospital

2021 ◽  
Author(s):  
Eda Çelebi Bitkin ◽  
Cengiz Kara ◽  
Gülay Can Yılmaz ◽  
Jamala Mammadova ◽  
Hasan Murat Aydın
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Tertiary Care ◽  
Normal Weight ◽  
Obese Group ◽  
Care Hospital ◽  
C Peptide

Abstract Objective: Obesity was once a rare problem in Type 1 diabetes mellitus, but is a growing problem today. The aim of our study is to determine the frequency of overweight / obesity at the time of diagnosis and during follow-up in children with type 1 diabetes mellitus as well as review the conditions that may accompany. Methods: 315 patients with type 1 diabetes mellitus were retrospectively analyzed. The patients were divided into two groups according to the last examination as normal weight and overweight / obese. The two groups were compared in terms of age at diagnosis, gender, birth weight, family history, anthropometric measurements, insulin dose used and blood pressure measurements, and insulin, c-peptide, hemoglobin A1c, triglyceride, and high-density lipoprotein levels at the time of diagnosis and follow-up. Results: The prevalence of overweight / obese in all patients was 4.8% at the time of diagnosis, while it was 9.8% at the last examination. The height, weight and BMI SD scores and c-peptide levels at the time of diagnosis of the overweight / obese group were higher than those with normal weight (p <0.001 and p = 0.008, respectively). The frequency of dyslipidemia and hypertension was higher in the overweight / obese group than in the normal weight group [18.2% versus 5% (p = 0.015) and 10% versus 1.5% (p = 0.003), respectively]. Conclusion: In our study, the fact that the overweight / obese group had higher BMI and c-peptide and lower HDL values at the time of diagnosis can be evaluated as indicators that insulin resistance syndrome can accompany T1DM from the beginning (double diabetes). When determining the treatment and follow-up strategies of patients with type 1 diabetes mellitus, considering the risk of obesity and taking the necessary precautions is very important in terms of morbidity.

scholarly journals Evaluation of children with type 1 diabetes mellitus in terms of overweight/obesity in tertiary care hospital

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Eda Celebi Bitkin ◽  
Cengiz Kara ◽  
Gülay Can Yılmaz ◽  
Jamala Mammadova ◽  
Hasan Murat Aydın
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Tertiary Care ◽  
Normal Weight ◽  
Obese Group ◽  
Care Hospital ◽  
C Peptide

Abstract Objectives Obesity is a growing problem in type 1 diabetes mellitus (T1DM) today. The aim of our study is to determine the frequency of overweight/obesity at the time of diagnosis and during follow-up in children with T1DM as well as review the conditions that may accompany. Methods A total of 315 patients with T1DM were retrospectively analyzed. The patients were divided into two groups as normal weight and overweight/obese. The two groups were compared in terms of age at diagnosis, birth weight, anthropometric measurements, insulin dose used and blood pressure measurements, and insulin, c-peptide, hemoglobin A1c, triglyceride, and high-density lipoprotein levels at the time of diagnosis and follow-up. Results The height, weight and body mass index standard deviation (BMI SD) scores, and c-peptide levels at the time of diagnosis of the overweight/obese group were higher than those with normal weight (p<0.001 and p = 0.008, respectively). The frequency of dyslipidemia and hypertension was higher in the overweight/obese group than in the normal weight group [18.2 vs. 5% (p = 0.015) and 10 vs. 1.5% (p = 0.003), respectively]. Conclusions In our study, the fact that the overweight/obese group had higher BMI and c-peptide and lower HDL values at the time of diagnosis can be evaluated as indicators that insulin resistance syndrome can accompany T1DM from the beginning (double diabetes). When determining the treatment and follow-up strategies of patients with T1DM, considering the risk of obesity and taking the necessary precautions is very important in terms of morbidity.

A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus

2018 ◽  
Vol 19 (4) ◽  
pp. 788-793 ◽  
Author(s):  
Perrin C White ◽  
Soumya Adhikari ◽  
Ellen K Grishman ◽  
Kathryn M Sumpter
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Phase I ◽  
Type 1 Diabetes Mellitus ◽  
Phase I Study ◽  
Adolescents And Adults ◽  
Anti Inflammatory
Sign in / Sign up

Export Citation Format

Share Document